logo
menu

Novozymes appoints new president and CEO

news item image
Biological solutions provider Novozymes has announced the appointment of Ester Baiget to position of president and CEO, effective 1 February 2020.

Baiget will succeed Peder Holk Nielsen who will be leaving the company in early 2020. She is currently business president for Dow’s Industrial Solutions business unit and a member of the executive leadership team.

Since joining Dow in 1995 as an engineer in Tarragona, Spain, Baiget has held a range of manufacturing, technical, commercial and strategic roles in the company. During her tenure as business president for Industrial Solutions, the unit has expanded the market, improved its position, and delivered double-digit growth and strong earnings.

“Ester is an experienced international leader with a very strong track-record within transformational change and driving profitable growth,” commented Jørgen Buhl Rasmussen, chairman of the board of directors of Novozymes. “Her experience is broad and global, and she is known for combining strong commercial credentials, technical expertise and an engaging, motivational leadership style.

“Ester is a leader who is used to running businesses with complex product portfolios and diverse groups of customers. Her ability to set the direction and operate in an R&D-driven environment together with her passion for the sustainability agenda makes her a great fit for Novozymes. The board and I look forward to working with Ester and build on the updated strategy Better Business with Biology.”

Commenting on her appointment, Baiget said: “I am looking so much forward to joining Novozymes – a company with a very strong purpose and an impressive product portfolio that bodes well for the future. As a person, I have always strived to make a difference, make the world a better place and help people grow. I see a very strong match between that and Novozymes.”